Miriam Kidron - 31 Dec 2025 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)

Signature
/s/ Miriam Kidron
Issuer symbol
ORMP
Transactions as of
31 Dec 2025
Net transactions value
$0
Form type
4
Filing time
05 Jan 2026, 17:21:03 UTC
Previous filing
11 Feb 2025
Next filing
21 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kidron Miriam Chief Scientific Officer, Director 1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK /s/ Miriam Kidron 05 Jan 2026 0001409232

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORMP Common Stock Award $0 +121,331 +10% $0.000000 1,314,664 31 Dec 2025 Direct F1
transaction ORMP Common Stock Award $0 +115,000 +8.7% $0.000000 1,429,664 31 Dec 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORMP Performance Stock Units Award $0 +19,000 $0.000000 19,000 31 Dec 2025 Common Stock 19,000 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer.
F2 Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.
F3 Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria.